Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension

Abstract Children with severe Group 1 pulmonary arterial hypertension (PAH) have an unpredictable response to subcutaneous treprostinil (TRE) therapy, which may be influenced by age, disease severity, or other unknown variables at time of initiation. In this retrospective single‐center cohort study,...

Full description

Bibliographic Details
Main Authors: Justin J. Kochanski, Jeffrey A. Feinstein, Michelle Ogawa, Victor Ritter, Rachel K. Hopper, Gregory T. Adamson
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Pulmonary Circulation
Subjects:
outcomes
prostacyclin
pulmonary hypertension
pulmonary vascular disease
Online Access:https://doi.org/10.1002/pul2.12328

Similar Items

Similar Items